A medical device assembly is disclosed. The medical device assembly includes a therapeusis delivery portion and an algometer portion. The therapeusis delivery portion includes a body having a proximal end and a distal end. The algometer portion includes a body having a proximal end and a distal end. The body of the therapeusis delivery portion defines a therapeusis-delivering passage and an algometer-receiving passage. The algometer-receiving passage may be sized to receive a portion of the algometer portion for connecting the algometer portion to the therapeusis delivery portion. A portion of medical device assembly is also disclosed. A method is also disclosed.
|
16. A portion of a medical device assembly, comprising:
a therapeusis delivery portion including a body having a proximal end and a distal end, wherein the body of the therapeusis delivery portion defines a therapeusis-delivering passage and an algometer-receiving passage that is sized to receive a portion of an algometer portion of the medical device assembly, thereby connecting the algometer portion to the therapeusis delivery portion and forming the medical device assembly, wherein the body of the therapeusis delivery portion includes:
a sheath, wherein the sheath includes an inner surface and an outer surface, and
wherein the inner surface of the sheath defines the algometer-receiving passage and extends from an opening in the proximal end of the body of the therapeusis delivery portion to the distal end of the body of the therapeusis delivery portion.
1. A medical device assembly, comprising:
a therapeusis delivery portion including a body having a proximal end and a distal end; and
an algometer portion including a body having a proximal end and a distal end,
wherein the body of the therapeusis delivery portion defines
a therapeusis-delivering passage and
an algometer-receiving passage, wherein the algometer-receiving passage is defined by an inner surface of the body of the therapeusis delivery portion, wherein the inner surface of the body of the therapeusis delivery portion extends from an opening in the proximal end of the body of the therapeusis delivery portion to the distal end of the body of the therapeusis delivery portion, and wherein the algometer-receiving passage is sized to receive a portion of the algometer portion for connecting the algometer portion to the therapeusis delivery portion.
2. The medical device assembly of
a handle portion; and
a wand portion.
3. The medical device assembly of
a sheath, wherein the sheath includes an inner surface and an outer surface, wherein the inner surface of the sheath defines the algometer-receiving passage.
4. The medical device assembly of
5. The medical device assembly of
6. The portion of medical device assembly of
7. The portion of medical device assembly of
8. The portion of medical device assembly
9. The portion of medical device assembly of
10. The medical device assembly of
one or more sensors connected to the distal end of the algometer portion; and
a processor communicatively-coupled to the one or more sensors.
11. The medical device assembly of
12. The medical device assembly of
13. The medical device assembly of
14. The medical device assembly of
one or more visual indicators attached to the body of the algometer, wherein the one or more visual indicators includes at least one of a light emitting diode and a liquid crystal display.
15. The medical device assembly of
one or more user input devices attached to the body of the algometer portion.
17. The portion of the medical device assembly of
18. The portion of medical device assembly of
19. The portion of medical device assembly of
20. The portion of medical device assembly of
21. The portion of medical device assembly of
22. A method, comprising:
disposing a force application sensor of an algometer portion of a medical device assembly according to
determining a level of pain being experienced by the patient; and
providing therapy to the locus of the patient by communicating therapeusis:
from a therapeusis container,
through a needle, and
to the locus.
23. The method of
assembling the medical device by connecting the therapeusis portion to the algometer portion.
24. The method of
disposing one or more sensors connected to the distal end of the algometer portion adjacent the locus of the patient; and
obtaining data from the one or more sensors.
25. The method of
obtaining an amount of force applied to the locus of the patient.
26. The method of
obtaining a measurement related to changes in nerve conduction or muscle spasms at or near the locus of the patient.
|
This U.S. patent application claims priority U.S. Provisional Patent Application 62/373,574, filed on Aug. 11, 2016, which is hereby incorporated by reference in its entirety.
This disclosure relates to a medical device assembly.
Various medical devices for determining a pain threshold of a patient are known in the art, such as, for example, algometers; an algometer is used to measure the pressure and/or force eliciting a pressure-pain threshold. While known medical devices have proven to be acceptable for such applications, such conventional medical devices are nevertheless susceptible to improvements that may enhance their overall performance and cost. Therefore, a need exists to develop improved medical devices and methodologies for utilizing the same that advance the art.
One aspect of the disclosure provides a medical device assembly. The medical device assembly includes a therapeusis delivery portion and an algometer portion. The therapeusis delivery portion includes a body having a proximal end and a distal end. The algometer portion includes a body having a proximal end and a distal end. The body of the therapeusis delivery portion defines a therapeusis-delivering passage and an algometer-receiving passage. The algometer-receiving passage may be sized to receive a portion of the algometer portion for connecting the algometer portion to the therapeusis delivery portion.
Implementations of the disclosure may include one or more of the following optional features. In some implementations, the algometer portion includes a handle portion and a wand portion. In some implementations, the algometer-receiving passage may be defined by one or more attachment clips. The one or more attachment clips includes a plurality of attachment clips. At least a first attachment clip of the plurality of attachment clips may be sized to connect to the handle portion of the algometer portion. At least a second attachment clip of the plurality of attachment clips may be sized to connect to the wand portion of the algometer portion.
In some instances, the body of the therapeusis delivery portion may be defined by a substantially tube shape. An inner surface of the body of the therapeusis delivery portion defines the therapeusis-delivering passage.
In some examples, the body of the therapeusis delivery portion includes a sheath. The sheath includes an inner surface and an outer surface. The inner surface of the sheath defines the algometer-receiving passage.
In some implementations, the sheath includes a proximal opening and an enclosed distal end. The proximal opening permits fluid communication with the algometer-receiving passage.
In some instances, the body of the therapeusis delivery portion may be defined by a substantially tube shape. An inner surface of the body of the therapeusis delivery portion defines the therapeusis-delivering passage.
In some examples, at least a portion of the enclosed distal end of the sheath includes an electrically-conductive material. In another example, all of a thickness of the enclosed distal end of the sheath may be formed from the electrically-conductive material.
In yet another example, a thickness of the enclosed distal end of the sheath may be formed from a first material and a second material. The first material may be a non-conductive material. The second material may be the electrically-conductive material. The electrically-conductive material may be impregnated within the non-conductive material.
In some implementations, a thickness of the enclosed distal end of the sheath may be bound by the inner surface of the sheath and the outer surface of the sheath. The conductive material may be disposed adjacent the outer surface of the sheath along the enclosed distal end of the sheath.
In some instances, the medical device further includes one or more sensors and a processor. The one or more sensors may be connected to the distal end of the algometer portion. The processor may be communicatively-coupled to the one or more sensors. The processor may be disposed within the body of the algometer portion. The one or more sensors may include a force application sensor. The one or more sensors may include an electromyography (EMG) sensor.
In some examples, the medical device further includes one or more visual indicators and one or more user input devices. The one or more visual indicators may be attached to the body of the algometer portion. The one or more visual indicators may include at least one of a light emitting diode and a liquid crystal display. The one or more user input devices may be attached to the body of the algometer portion.
Another aspect of the disclosure provides a portion of medical device assembly. The portion of medical device assembly includes a therapeusis delivery portion. The therapeusis delivery portion includes a body having a proximal end and a distal end. The body of the therapeusis delivery portion may define a therapeusis-delivering passage and an algometer-receiving passage that may be sized to receive a portion of an algometer portion of the medical device assembly, thereby connecting the algometer portion to the therapeusis delivery portion and forming the medical device assembly. The body of the therapeusis delivery portion includes a sheath. The sheath includes an inner surface and an outer surface. The inner surface of the sheath may define the algometer-receiving passage.
Implementations of the disclosure may include one or more of the following optional features. In some implementations, the sheath includes a proximal opening and an enclosed distal end. The proximal opening permits fluid communication with the algometer-receiving passage.
In some implementations, at least a portion of the enclosed distal end of the sheath may include an electrically-conductive material. In other implementations, all of a thickness of the enclosed distal end of the sheath may be formed from the electrically-conductive material.
In other implementations, a thickness of the enclosed distal end of the sheath may be formed from a first material and a second material. The first material may be a non-conductive material. The second material may be the electrically-conductive material. The electrically-conductive material may be impregnated within the non-conductive material.
In some instances, a thickness of the enclosed distal end of the sheath may be bound by the inner surface of the sheath and the outer surface of the sheath. The conductive material may be disposed adjacent the outer surface of the sheath along the enclosed distal end of the sheath.
In yet another aspect of the disclosure provides a method. The method includes disposing a force application sensor of an algometer portion of a medical device assembly adjacent a locus of a patient; determining a level of pain being experienced by the patient; and providing therapy to the locus of the patient by communicating therapeusis from a therapeusis container through a needle and to the locus.
Implementations of the disclosure may include one or more of the following optional features. In some implementations, prior to the disposing step, the method includes: assembling the medical device by connecting a therapeusis delivery portion to an algometer portion. The therapeusis delivery portion may include a body. The algometer portion may include a body having a proximal end and a distal end. The body of the therapeusis delivery portion may define a therapeusis-delivering passage. A portion of the algometer portion is disposed within the algometer-receiving passage for assembling the medical device.
In some implementations, the method further includes disposing one or more sensors connected to the distal end of the algometer portion adjacent the locus of the patient; and obtaining data from the one or more sensors. The method may further include obtaining an amount of force applied to the locus of the patient. The method may further include obtaining a measurement related to changes in nerve conduction or muscle spasms at or near the locus of the patient.
The details of one or more implementations of the disclosure are set forth in the accompanying drawings and the description below. Other aspects, features, and advantages will be apparent from the description and drawings, and from the claims.
Like reference symbols in the various drawings indicate like elements.
Referring to
The body 12B of the therapeusis delivery portion 12 may form a tube-shaped body having a therapeusis-delivering passage 16 (see, e.g.,
The body 14B of the algometer portion 14 includes a handle portion 14B1 and a wand portion 14B2. The handle portion 14B1 includes the proximal end 14P of the algometer portion 14 and the wand portion 14B2 includes the distal end 14D of the algometer portion 14. The handle portion 14B1 and the wand portion 14B2 may be respectively defined by a diameter D14-1, D14-2; the diameter D14-1 of the handle portion 14B1 may be greater than the diameter D14-2 of the wand portion 14B2.
As seen in
As seen in
As seen in
In some implementations, the flexible needle N and therapeusis container C may be a conventional syringe S. In an example, one or more of the flexible needle N and the therapeusis container C may be directly interfaced with the medical device assembly 10. In other example, one or more of the flexible needled N and the therapeusis container C may not be directly interfaced (i.e., one or more of the flexible needle N and the therapeusis container may be ‘indirectly’ interfaced) with the medical device assembly 10 in, for example, a free-floating arrangement such that an operator holds, for example, one or both of the therapeusis delivery portion 12 and the algometer portion 14 with one hand and then the operator operates/holds flexible needle N and/or the therapeusis container C with his/her other hand. In an example, if the flexible needle N and the therapeusis container C form a syringe S, the syringe S may be interfaced with the therapeusis delivery portion 12 by way of, for example, a threaded connection (by way of, e.g., a Luer lock, not shown).
With reference to
Prior to interfacing the flexible needle N with the medical device assembly 10 as seen in
With reference to
As seen in
In other examples, the first and second axes A14-A14, A12-A12 extending through each of the body 14B of the algometer portion 14 and the tube-shaped body 12B of the therapeusis delivery portion 12 may not axially deviate along their respective axes A14-A14, A12-A12. Because each of the body 14B of the algometer portion 14 and the tube-shaped body 12B of the therapeusis delivery portion 12 may not axially deviate along their respective axes A14-A14, A12-A12 (i.e., each of the first and second axes A14-A14, A12-A12 may remain substantially linear), the body 14B of the algometer portion 14 and the tube-shaped body 12a of the therapeusis delivery portion 12 may remain parallel to one another.
The design of the algometer portion 14 and the therapeusis delivery portion 12 to include an angular deviation (if any) along their respective axes A14-A14, A12-A12 as described above may depend on the application of the medical device assembly 10. For example, if the medical device assembly 10 is to be utilized for determining pain and/or treating pain in a vaginal region of a patient P, the first angle θ1 and the second angle θ2 may be approximately equal to about 70°. In another example, if the medical device assembly 10 is utilized for endoscopically determining pain and/or treating pain of a patient P (by, e.g., disposing the force application sensor 26a against the patient's skin), the first angle θ1 and the second angle θ2 may be approximately equal to about 0°. In yet another example, if the medical device assembly 10 is utilized for superficially determining pain and/or treating pain of a patient P (by, e.g., disposing the force application sensor 26a against the patient's skin), the first angle θ1 and the second angle θ2 may be approximately equal to about 0°. In some instances, if the medical device assembly 10 is utilized in an ear-nose-throat (ENT) application for determining pain and/or treating pain of a patient P (by, e.g., disposing the force application sensor 26a against the larynx), the first angle θ1 and the second angle θ2 may be between approximately equal to about 0° and 45°. In another implementation, if the medical device assembly 10 is utilized in dental application for determining pain and/or treating pain of a patient P (e.g., by disposing the force application sensor 26a adjacent a patient's gums), the first angle θ1 and the second angle θ2 may be between approximately equal to about 0° and 270°.
Referring to
The force application sensor 26a may comprise a strain gauge or other component for measuring the application of force F in a small amount (e.g., 0.1 to 100 grams) that measures forces F directed to a surface of the patient P as a result of an operator of the medical device assembly 10: (1) gripping the handle portion 14B1 of the body 14B of the algometer portion 14 and (2) pushing the force application sensor 26a toward the surface of the patient P. In some instances, the strain gauge may comprise a Ni—Cu Metal foil construction. In some implementations, the strain gauge may determine a range of input forces F between about 0N to 1N, 0N to 5N, or 0N to 10N. In some examples, the strain gauge may include the following dimensions: 720.639 mm in length, 10 microns in width and 0.05 microns in thickness. In some instances, the stain gauge may be defined by a resistance equal to approximately about 706.226 kΩ. In other examples, an exemplary strain gauge may be commercially available from Strain Measurement Devices under the name S256.
As seen in
The processor 34 may also be connected to an accelerometer (not shown) disposed within the body 14B of the algometer portion 14 to allow for the storage of spatial coordinate positions of the medial device assembly 10 for allowing clinicians to determine the success or failure of previously-applied therapy to a previously-examined surface area of the patient P over a period of time. The force data could be recorded and saved in data collection software (e.g., MICROSOFT EXCEL®) of the computer workstation W. In some instances, any portion of the medical device assembly 10 may include, for example, indicia, lines, markings or the like in order to spatially assist the operator in determining, for example, depth of insertion of the medical device assembly 10 within a body cavity of the patient P.
The processor 34 may be connected to other components that may or may not be associated with the medical device assembly 10. In some instances, other components may include, for example: a battery, one or more light emitting diodes (LEDs) 30, a liquid crystal display (LCD), buttons 32 or the like. In an example, the LCD may display force values measured from the force application sensor 26a in order to permit, for example, a clinician to immediately visually determine an amount of force F being applied to a patient P by the algometer portion 14. In some instances, the one or more LEDs 30 may be illuminated when the medical device assembly 10 is powered on. In other examples, the one or more LEDs 30 may be illuminated when the processor 34 is paired with the computer workstation W for communicating force data thereto. In other examples, the one or more other components may also include the EMG sensor 26b that measures changes in nerve conduction or muscle spasms.
Other components connected to the electronics may include a battery disposed within the body 14B of the algometer portion 14. The specifications of the battery may be dependent upon an overall power consumption of the medical device assembly 10. In some examples, power consumption considerations of the medical device assembly 10 may include: strain gauge bias voltage of the force application sensor 26a, Wheatstone bridge input voltage, the supply voltage of the one or more LEDs 30 and the like. The bias and input voltage of the sensor strain gauge and Wheatstone bridge may require approximately 3V to 5V. The electronics may be at different potentials, which may require voltage steps (up/down) that may be addressed by a voltage regulator circuit connected to, for example, a single AAA battery with a 1.5V rating.
Upon the operator of the medical device assembly 10 pushing the force application sensor 26a toward the surface of the patient P and locating a specific spatial area of discomfort of the patient, the operator may (1) guide the flexible needle N through the tube-shaped body 12B of the therapeusis delivery portion 12 and (2) optionally arrange the flexible needle N for contact with the area of discomfort of the patient P. Then, the operator may actuate the syringe S for delivering therapeusis: (1) from the therapeusis container C, (2) through the flexible needle N and (3) into to the area of discomfort of the patient P for providing therapy to the patient P. The therapeusis contained by the therapeusis container C that is ultimately delivered to the area of discomfort of the patient P may include, for example, a pharmaceutical, anesthetic or the like. Although an exemplary embodiment described above is directed to an externally-located therapeusis container C containing the therapeusis, other implementations may include a therapeusis container C stowed within, for example, the algometer portion 14 such that a user may actuate, for example, a button 32 for causing therapeusis to be delivered from the therapeusis container C from the algometer portion 14 to the area of discomfort of the patient P. Furthermore, the therapeusis may be delivered without using a flexible needle N (e.g., the therapeusis may be pumped through the tube-shaped body 12B of the therapeusis delivery portion 12 for topical delivery to the area of discomfort of the patient P.
An exemplary amplification of the Wheatstone Bridge Output Voltage is now discussed. Micro-electro-mechanical-systems (MEMS) devices may have a supply voltage of up to 100V but only output a voltage on the order of microns (Froehlich, n.d.). Due to this low output, it may have a gain amplifier that will amplify the measurable quantity that the sensor outputs. The output voltage for the Wheatstone bridge in the pressure-sensing device should be amplified in order for the interface circuits to be able to properly measure the voltage. Typical microcontroller inputs operate with an input of 0-3.3 volts (Froehlich, n.d.). An applicable device that was chosen to amplify the bridge output voltage is an operational amplifier (op-amp). The configuration of the operational amplifier will be in the form of a non-inverting op-amp. The image below shows a non-inverting operational amplifier.
The fabrication of operational amplifiers makes it so that there is a very large input impendence on the input terminals of the device. As a result, the current going into these terminals are so small that their amounts are negligible. The input of this amplifier will be the output voltage of the bridge circuit of the pressure sensor. Below is the equation for the output of the non-inverting op-amp, in relation to the input voltage:
Looking at the above equation (Eq. 2), the gain of the amplifier, K, is
The gain is dependent on the values of resistors R1 and R2. These resistors will be chosen such that the output voltage of the operational amplifier will be in an adequate range to be read by other electronics. This gain will be selected after the device is actually fabricated and the output voltage can actually be tested.
In order for the users to know how much force F is being applied to the force application sensor 26a, it may create a function that depends on the force F being applied. This function may be related to the applied force F of the amplified output voltage from the Wheatstone bridge. This will be done in the laboratory. A machine will apply many increments of known forces F to the force application sensor 26a and the corresponding output voltages from the bridge will be recorded. These data points will be plotted with output voltage on the y-axis and applied force F on the x-axis. After all of the data points have been collected software, such as MATLAB, will be used to realize the equation of the line from the data points.
Calibration of the force application sensor 26a may be done in order to ensure accurate voltage-to-force conversions. For example, if the Wheatstone bridge has an output voltage of 1 volt at equilibrium (when no force F is being applied), rather than zero, this 1 volt may correlate to no force F being applied to the force application sensor 26a.
In some implementations, the electronics may include Texas Instrument (TI) CP3SP33 Connectivity Processor with Cache, Digital Signal Processor (DSP), Bluetooth, USB and a dual Controller Area Network (CAN) Interface to provide the processing power of the interface. The TI DSP could be able to pair with its corresponding USB hub device. This will enable the transmitting and receiving functionality of the DSP. The chip could contain an analog to digital converter to take the diaphragm voltage signal from the sensor and convert it to force F. The force F could then be transmitted to the computer workstation (e.g., a paired laptop) and stored in a data file (TI, 2014).
Referring to
The body 112B of the therapeusis delivery portion 112 is similar to the body 12B of the therapeusis delivery portion 12 described above at
The sheath 118 may be made substantially similar to a condom or prophylactic that promotes cleanliness or mitigates bacterial contamination of the portion L114-2 of the length L114 of the body 114B of the algometer portion 114. The sheath 118 may be made from any desirable material such as silicone, latex, plastic, any prophylactic material or the like. Although the sheath 118 may be made from one material (such as, e.g., a non-electrically-conductive material), the sheath 118 may include two or more materials. Exemplary examples of the sheath 118 including more than one material (e.g., a first, non-electrically-conductive material M1 and a second, electrically-conductive material M2) will be described in the following disclosure at
The sheath 118 generally includes a tube-shaped body 118B having a proximal opening 118P and an enclosed distal end 118D. The tube-shaped body 118B includes an inner surface 118I (see, e.g.,
As seen in
With reference to
Referring to
The body 114B of the algometer portion 114 includes the handle portion 114B1 and the wand portion 114B2. The handle portion 114B1 includes the proximal end 114P of the algometer portion 114 and the wand portion 114B2 includes the distal end 114D of the algometer portion 114. The handle portion 114B1 and the wand portion 114B2 may be respectively defined by a diameter D114-1, D114-2; the diameter D114-1 of the handle portion 114B1 may be greater than the diameter D114-2 of the wand portion 114B2.
As seen in
In some implementations, the flexible needle N and therapeusis container C may be a conventional syringe S. In an example, one or more of the flexible needle N and the therapeusis container C may be directly interfaced with the medical device assembly 100. In other example, one or more of the flexible needled N and the therapeusis container C may not be directly interfaced (i.e., one or more of the flexible needle N and the therapeusis container may be ‘indirectly’ interfaced) with the medical device assembly 100 in, for example, a free-floating arrangement such that an operator holds, for example, one or both of the therapeusis delivery portion 112 and the algometer portion 114 with one hand and then the operator operates/holds flexible needle N and/or the therapeusis container C with his/her other hand. In an example, if the flexible needle N and the therapeusis container C form a syringe S, the syringe S may be interfaced with the therapeusis delivery portion 112 by way of, for example, a threaded connection (by way of, e.g., a Luer lock, not shown).
With reference to
Referring to
At least a first portion of the body 114B of the algometer portion 114 may axially extend along a first axis A114-A114, and, in some instances as seen in
As seen in
In other examples, the first and second axes A114-A114, A112-A112 extending through each of the body 114B of the algometer portion 114 and the tube-shaped body 112B of the therapeusis delivery portion 112 may not axially deviate along their respective axes A114-A114, A112-A112. Because each of the body 114B of the algometer portion 114 and the tube-shaped body 112B of the therapeusis delivery portion 112 may not axially deviate along their respective axes A114-A114, A112-A112 (i.e., each of the first and second axes A114-A114, A112-A112 may remain substantially linear), the body 114B of the algometer portion 114 and the tube-shaped body 112B of the therapeusis delivery portion 112 may remain parallel to one another.
The design of the algometer portion 114 and the therapeusis delivery portion 112 to include an angular deviation (if any) along their respective axes A114-A114, A112-A112 as described above may depend on the application of the medical device assembly 100. For example, if the medical device assembly 100 is to be utilized for determining pain and/or treating pain in a vaginal region of a patient P, the first angle θ1 and the second angle θ2 may be approximately equal to about 70°. In another example, if the medical device assembly 100 is utilized for endoscopically determining pain and/or treating pain of a patient P (by, e.g., disposing the force application sensor 126a against the patient's skin), the first angle θ1 and the second angle θ2 may be approximately equal to about 0°. In yet another example, if the medical device assembly 100 is utilized for superficially determining pain and/or treating pain of a patient P (by, e.g., disposing the force application sensor 126a against the patient's skin), the first angle θ1 and the second angle θ2 may be approximately equal to about 00. In some instances, if the medical device assembly 100 is utilized in an ear-nose-throat (ENT) application for determining pain and/or treating pain of a patient P (by, e.g., disposing the force application sensor 126a against the larynx), the first angle θ1 and the second angle θ2 may be between approximately equal to about 0° and 45°. In another implementation, if the medical device assembly 100 is utilized in dental application for determining pain and/or treating pain of a patient P (e.g., by disposing the force application sensor 126a adjacent a patient's gums), the first angle θ1 and the second angle θ2 may be between approximately equal to about 0° and 270°.
Referring to
The force application sensor 126a may comprise a strain gauge or other component for measuring the application of force F in a small amount (e.g., 0.1 to 100 grams) that measures forces F directed to a surface of the patient P as a result of an operator of the medical device assembly 100: (1) gripping the handle portion 114B1 of the body 114B of the algometer portion 114 and (2) pushing the force application sensor 126a toward the surface of the patient P. In some instances, the strain gauge may comprise a Ni—Cu Metal foil construction. In some implementations, the strain gauge may determine a range of input forces F between about 0N to 1N, 0N to 5N, or 0N to 10N. In some examples, the strain gauge may include the following dimensions: 720.639 mm in length, 10 microns in width and 0.05 microns in thickness. In some instances, the stain gauge may be defined by a resistance equal to approximately about 706.226 kΩ. In other examples, an exemplary strain gauge may be commercially available from Strain Measurement Devices under the name S256.
With reference to
The processor 134 may also be connected to an accelerometer (not shown) disposed within the body 114B of the algometer portion 114 to allow for the storage of spatial coordinate positions of the medial device assembly 100 for allowing clinicians to determine the success or failure of previously-applied therapy to a previously-examined surface area of the patient P over a period of time. The force data could be recorded and saved in data collection software (e.g., MICROSOFT EXCEL®) of the computer workstation W. In some instances, any portion of the medical device assembly 100 may include, for example, indicia, lines, markings or the like in order to spatially assist the operator in determining, for example, depth of insertion of the medical device assembly 10 within a body cavity of the patient P.
The processor 134 may be connected to other components that may or may not be associated with the medical device assembly 100. In some instances, other components may include, for example: a battery, one or more light emitting diodes (LEDs) 130, a liquid crystal display (LCD), buttons 132 or the like. In an example, the LCD may display force values measured from the force application sensor 126a in order to permit, for example, a clinician to immediately visually determine an amount of force F being applied to a patient P by the algometer portion 114. In some instances, the one or more LEDs 130 may be illuminated when the medical device assembly 100 is powered on. In other examples, the one or more LEDs 130 may be illuminated when the processor 134 is paired with the computer workstation W for communicating force data thereto. In other examples, the one or more other components may also include the EMG sensor 126b that measures changes in nerve conduction or muscle spasms.
Other components connected to the electronics may include a battery disposed within the body 114B of the algometer portion 114. The specifications of the battery may be dependent upon an overall power consumption of the medical device assembly 100. In some examples, power consumption considerations of the medical device assembly 100 may include: strain gauge bias voltage of the force application sensor 126a, Wheatstone bridge input voltage, the supply voltage of the one or more LEDs 130 and the like. The bias and input voltage of the sensor strain gauge and Wheatstone bridge may require approximately 3V to 5V. The electronics may be at different potentials, which may require voltage steps (up/down) that may be addressed by a voltage regulator circuit connected to, for example, a single AAA battery with a 1.5V rating.
Upon the operator of the medical device assembly 100 pushing the force application sensor 126a toward the surface of the patient P and locating a specific spatial area of discomfort of the patient, the operator may (1) guide the flexible needle N through the tube-shaped body 112B of the therapeusis delivery portion 112 and (2) optionally arrange the flexible needle N for contact with the area of discomfort of the patient P. Then, the operator may actuate the syringe S for delivering therapeusis: (1) from the therapeusis container C, (2) through the flexible needle N and (3) into to the area of discomfort of the patient P for providing therapy to the patient P. The therapeusis contained by the therapeusis container C that is ultimately delivered to the area of discomfort of the patient P may include, for example, a pharmaceutical, anesthetic or the like. Although an exemplary embodiment described above is directed to an externally-located therapeusis container C containing the therapeusis, other implementations may include a therapeusis container C stowed within, for example, the algometer portion 114 such that a user may actuate, for example, a button 132 for causing therapeusis to be delivered from the therapeusis container C from the algometer portion 114 to the area of discomfort of the patient P. Furthermore, the therapeusis may be delivered without using a flexible needle N (e.g., the therapeusis may be pumped through the tube-shaped body 112B of the therapeusis delivery portion 112 for topical delivery to the area of discomfort of the patient P.
An exemplary amplification of the Wheatstone Bridge Output Voltage is now discussed. Micro-electro-mechanical-systems (MEMS) devices may have a supply voltage of up to 100V but only output a voltage on the order of microns (Froehlich, n.d.). Due to this low output, it may have a gain amplifier that will amplify the measurable quantity that the sensor outputs. The output voltage for the Wheatstone bridge in the pressure-sensing device should be amplified in order for the interface circuits to be able to properly measure the voltage. Typical microcontroller inputs operate with an input of 0-3.3 volts (Froehlich, n.d.). An applicable device that was chosen to amplify the bridge output voltage is an operational amplifier (op-amp). The configuration of the operational amplifier will be in the form of a non-inverting op-amp. The image below shows a non-inverting operational amplifier.
The fabrication of operational amplifiers makes it so that there is a very large input impendence on the input terminals of the device. As a result, the current going into these terminals are so small that their amounts are negligible. The input of this amplifier will be the output voltage of the bridge circuit of the pressure sensor. Below is the equation for the output of the non-inverting op-amp, in relation to the input voltage:
Looking at the above equation (Eq. 2), the gain of the amplifier, K, is
The gain is dependent on the values of resistors R1 and R2. These resistors will be chosen such that the output voltage of the operational amplifier will be in an adequate range to be read by other electronics. This gain will be selected after the device is actually fabricated and the output voltage can actually be tested.
In order for the users to know how much force F is being applied to the force application sensor 126a, it may create a function that depends on the force F being applied. This function may be related to the applied force F of the amplified output voltage from the Wheatstone bridge. This will be done in the laboratory. A machine will apply many increments of known forces F to the force application sensor 126a and the corresponding output voltages from the bridge will be recorded. These data points will be plotted with output voltage on the y-axis and applied force F on the x-axis. After all of the data points have been collected software, such as MATLAB, will be used to realize the equation of the line from the data points.
Calibration of the force application sensor 126a may be done in order to ensure accurate voltage-to-force conversions. For example, if the Wheatstone bridge has an output voltage of 1 volt at equilibrium (when no force F is being applied), rather than zero, this 1 volt may correlate to no force F being applied to the force application sensor 126a.
In some implementations, the electronics may include Texas Instrument (TI) CP3SP33 Connectivity Processor with Cache, Digital Signal Processor (DSP), Bluetooth, USB and a dual Controller Area Network (CAN) Interface to provide the processing power of the interface. The TI DSP could be able to pair with its corresponding USB hub device. This will enable the transmitting and receiving functionality of the DSP. The chip could contain an analog to digital converter to take the diaphragm voltage signal from the sensor and convert it to force F. The force F could then be transmitted to the computer workstation (e.g., a paired laptop) and stored in a data file (TI, 2014).
A number of implementations have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the disclosure. Accordingly, other implementations are within the scope of the following claims. For example, the actions recited in the claims can be performed in a different order and still achieve desirable results.
Peters, Kenneth, Ottolino, Rocco, Megahan, Gregory, Carrico, Donna J.
Patent | Priority | Assignee | Title |
Patent | Priority | Assignee | Title |
4928707, | Mar 17 1987 | Regents of the University of Minnesota; REGENTS OF THE UNIVERSITY OF MINNESOTA, MORRILL HALL, 100 CHURCH STREET S E , MINNEAPOLIS, MN 55455, A CORP OF MN | Electronic pressure algometer apparatus |
5533514, | May 09 1995 | Universite de Montreal | Algometry management system |
5592947, | May 09 1995 | Universite de Montreal | Algometer with pressure intensification rate adjusting and control capabilities |
6306101, | Apr 14 2000 | IITC Inc. | Electronic device for measuring sensory thresholds in humans and animals |
8224464, | May 07 2007 | NEW PELVIC PAIN TECHNOLOGIES INC | Method and apparatus for treating pelvic pain |
8337435, | May 07 2007 | NEW PELVIC PAIN TECHNOLOGIES INC | Method and apparatus for treating pelvic pain |
8632482, | May 07 2007 | NEW PELVIC PAIN TECHNOLOGIES INC | Method and apparatus for treating pelvic pain |
8639360, | May 07 2007 | NEW PELVIC PAIN TECHNOLOGIES INC | Method and apparatus for treating pelvic pain |
20100132058, | |||
20110144541, | |||
20130244233, | |||
20140073999, | |||
20140088469, | |||
20140275846, | |||
20140276549, | |||
20150127077, | |||
20170087364, |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Aug 10 2017 | WILLIAM BEAUMONT HOSPITAL | (assignment on the face of the patent) | / | |||
Feb 08 2021 | CARRICO, DONNA | WILLIAM BEAUMONT HOSPITAL | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 055686 | /0316 | |
Feb 09 2021 | MEGAHAN, GREGORY | WILLIAM BEAUMONT HOSPITAL | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 055686 | /0316 | |
Feb 09 2021 | OTTOLINO, ROCCO | WILLIAM BEAUMONT HOSPITAL | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 055686 | /0316 | |
Mar 18 2021 | PETERS, KENNETH | WILLIAM BEAUMONT HOSPITAL | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 055686 | /0316 |
Date | Maintenance Fee Events |
Dec 11 2024 | M2551: Payment of Maintenance Fee, 4th Yr, Small Entity. |
Date | Maintenance Schedule |
Jun 29 2024 | 4 years fee payment window open |
Dec 29 2024 | 6 months grace period start (w surcharge) |
Jun 29 2025 | patent expiry (for year 4) |
Jun 29 2027 | 2 years to revive unintentionally abandoned end. (for year 4) |
Jun 29 2028 | 8 years fee payment window open |
Dec 29 2028 | 6 months grace period start (w surcharge) |
Jun 29 2029 | patent expiry (for year 8) |
Jun 29 2031 | 2 years to revive unintentionally abandoned end. (for year 8) |
Jun 29 2032 | 12 years fee payment window open |
Dec 29 2032 | 6 months grace period start (w surcharge) |
Jun 29 2033 | patent expiry (for year 12) |
Jun 29 2035 | 2 years to revive unintentionally abandoned end. (for year 12) |